Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 22 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 19 20 21 22 presentations: 1 to 25 of 545
Immuno-oncology Clinical Trials I
Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Michael Postow
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Padmanee Sharma
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
Matteo Carlino
Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Wentworthville, Australia
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Charles G. Drake
Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
Yong-Chen Lu
National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Jedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Precision Medicine Early Clinical Trials
Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Udai Banerji
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 "CREATE"
Patrick Schoffski
University Hospitals Leuven - Department of General Medical Oncology, Leuven, Belgium
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Ravi Salgia
City of Hope, Duarte, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results
Alexander Drilon
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
David S Hong
MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Leena Gandhi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Inhibiting immune checkpoints
Mary L. Disis
University of Washington, Seattle, WA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Regulatory T cells
Dario A. Vignali
Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Regulatory myeloid cells
Dmitry I. Gabrilovich
The Wistar Institute, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Galectins and immune response in cancer
Gabriel A. Rabinovich
Instituto de BiologĂ­a y Medicina Experimental, CONICET, Ciudad de Buenos Aires, Argentina
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Chairperson
Elizabeth M. Jaffee
Johns Hopkins University, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Successes and challenges in designing combination immunotherapy clinical trials for breast cancer
Leisha A Emens
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Issues faced by industry in developing safe and effective combination immunotherapies
Ira Mellman
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Statistical challenges in designing combination immunotherapy clinical trials
Katy Simonsen
Bristol-Myers Squibb Co., Princeton, NJ, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
FDA's point of view on trial designs for accelerating combination immunotherapies across multiple tumor types
Tatiana Prowell
U.S. Food and Drug Administration, Silver Spring, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Integrating Tumor Heterogeneity into Epidemiologic Studies: New Perspectives on Cancer Etiology
Methods for defining tumor heterogeneity in epidemiologic studies
David L. Rimm
Yale University School of Medicine, Branford, CT, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Integrating Tumor Heterogeneity into Epidemiologic Studies: New Perspectives on Cancer Etiology
Assessing associations in etiological studies of tumor sub-types: Interpretation and potential biases
Lorenzo Richiardi
Univ. of Turin, Turin, Italy
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
<< first | < prev page: of 22 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 19 20 21 22 presentations: 1 to 25 of 545